At its meeting on 24 June 2024, the Transparency Council adopted opinion No. 99/2024 on the inclusion in reimbursement of medicines containing the active substances atorvastatinum, lovastatinum, simvastatinum in the scope of indications for use or dosage or method of administration different from those specified in the Summary of Product Characteristics
Publication on the list of opinions on active substances for off-label indications >>